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Abstract
Prediction of cancer recurrence in patients with non-small cell lung cancer (NSCLC) currently relies on the assessment of
clinical characteristics including age, tumor stage, and smoking history. A better prediction of early stage cancer patients
with poorer survival and late stage patients with better survival is needed to design patient-tailored treatment protocols.
We analyzed gene expression in RNA from peripheral blood mononuclear cells (PBMC) of NSCLC patients to identify
signatures predictive of overall patient survival. We find that PBMC gene expression patterns from NSCLC patients, like
patterns from tumors, have information predictive of patient outcomes. We identify and validate a 26 gene prognostic
panel that is independent of clinical stage. Many additional prognostic genes are specific to myeloid cells and are more
highly expressed in patients with shorter survival. We also observe that significant numbers of prognostic genes change
expression levels in PBMC collected after tumor resection. These post-surgery gene expression profiles may provide a means
to re-evaluate prognosis over time. These studies further suggest that patient outcomes are not solely determined by tumor
gene expression profiles but can also be influenced by the immune response as reflected in peripheral immune cells.
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Introduction
Lung cancer is the most common cause of cancer mortality
worldwide, accounting for 157,300 cancer deaths in the United
States alone in 2010 [1]. The overall five-year survival for lung
cancer is 16%, and prognosis is strongly associated with the disease
stage at diagnosis [2]. Non-small cell lung cancer (NSCLC)
accounts for 80% of all lung cancer cases.
Treatment protocols and prognostic assessments of patients with
NSCLC are based primarily on TNM stage. Surgical resection for
early stage disease (Stage I, II, and some Stage III) remains the
standard of care. Unfortunately, 30–60% of patients (depending
on stage) will develop a recurrence and die of their disease, leading
to a 5-year survival rate of 35–70% for patients after resection.
Clearly there is an unmet need for additional prognostic factors for
a more informed process of treatment.
There is significant heterogeneity in clinical outcomes for
patients with early stage NSCLC and the basis is unknown.
Several previous studies focused on gene expression in surgically
excised tumors to identify prognostic signatures were recently
reviewed [3,4]. None is yet approved for clinical application.
We previously showed that patients with NSCLC have
significant gene expression changes in their PBMC which provide
useful diagnostic markers (5) and this PBMC cancer signature is
reduced or eliminated in a subset of patients retested after tumor
resection [5]. Since the changes in PBMC gene expression are a
reflection of the interactions of the tumor and the immune system,
we have now analyzed our gene expression data and demonstrate
a signature associated with overall survival. We also show that
some PBMC genes associated with survival change their
expression in samples taken after tumor resection and might
provide an additional indicator of recurrence.
Materials and Methods
Study population
A total of 137 patients with newly diagnosed, histopathologically
confirmed, non-small cell lung cancer (NSCLC) were recruited
from the University of Pennsylvania Medical Center during the
period 2003 through 2007. Written informed consent was received
from all participants involved in the study and samples were
collected with approval of both University of Pennsylvania IRB
and Wistar IRB. For this analysis, only subjects with Stage I-IIIA
NSCLC who underwent surgical resection with curative intent
were included. Exclusion criteria included sub-lobar resection,
positive resection margins, and death within 30 days of surgery.
This resulted in the inclusion of 108 subjects in this analysis
(Table S1). All participants had blood collection prior to surgery
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Table 1 summarizes the major prognostic parameters as
identified by the National Cancer Comprehensive Network
(NCCN) for our study population. Clinical outcome and survival
information was obtained via chart review, phone contact, or from
the Social Security Death Index (SSDI).
PBMC Collection and Processing
Blood samples were drawn at the University of Pennsylvania
Medical Center in two ‘‘CPT’’ tubes (Becton Dickinson).
Peripheral blood mononuclear cells (PBMC) were isolated within
90 minutes of blood draw, washed in PBS, transferred into
RNAlater (Ambion), and then stored at 4uC overnight before
transfer to 280uC. RNA purification was carried out using
TriReagent (Molecular Research), as recommended, and con-
trolled for quality using the Bioanalyzer. Only samples with 28S/
16S ratios of .0.75 were used for further studies. A constant
amount (400 ng) of total RNA was amplified, as recommended by
Illumina, for gene expression analysis.
Microarray preprocessing
Samples were processed and hybridized to the Illumina WG-
6v2 human whole genome bead arrays. All arrays were processed
at the Wistar Institute Genomics Facility as previously described
[6] and then gene expression values were log2 transformed for
further analysis. The array data used for these studies are publicly
available in the GEO database through the accession number
GSE13255. Table S1 lists the 108 subjects used for analysis.
Statistical Methods
Risk factor analysis. Univariate Cox regression analysis was
performed to test the association of clinical risk factors and
individual gene expression with overall survival. Multivariate Cox
regression was used to test the association of a combination of
factors. Statistical significance was defined as P,0.05. False
discovery rate for gene association with overall survival was
determined according to Storey et. al. [7]. Association of overall
survival with tumor stage was done both by treating stage as a
continuous variable and as two groups: stage I and a combined
stage II plus III. The results were significant for both approaches
with the univariate and multivariate regression analyses. Because
the number of stage II tumors was small (14 patients) and even
smaller when the data was split into training and independent
validation sets, we decided to combine stage II and III to have a
larger group size in the validation step. We used the combination
of stage II and III throughout the manuscript for consistency.
Kaplan-Meier curves. Kaplan-Meier curves were plotted
using Matlab v7.2 based on censored survival data. Patients were
stratified by factor median unless stated otherwise.
Gene panel selection. To identify a set of genes associated
with overall survival we split the 108 sample dataset into training
and testing sets of equal size (54 random samples in each). The
training set was first analyzed to identify an outcome-informative
gene panel by identifying probes with the lowest mean univariate
Cox regression p-value across 50 tests of 40 random samplings
(75% of the training set). The top 100 genes were then used for
multivariate Cox regression with L1 and L2 penalized estimations
[8]. The final l1 and l2 hyperparameter pair selected gave the
best performance using 10-fold cross-validation on the training set.
This method results in a model consisting of N genes that have
non-zero regression coefficients c1…cN. Those coefficients along
with corresponding gene expression data for any patient i (X1i…
XNi) were used to calculate a gene prognostic score (GPS) for the
patient as follows: GPS=c1X1j+…+cNXNj.
Independent validation of the predictive gene
panel. The 54 patients set aside and not used for predictive
gene selection were used as an independent test set for evaluation
of the model developed on the training set. Significance of the
GPS as a prognostic factor on the external validation set was
estimated by univariate Cox regression. Independence of the GPS
and Stage factors were tested by multivariate Cox regression.
Testing robustness of the gene panel selection. To show
that the significance of independent validation (performance) of
the GPS model on the testing set did not depend on the particular
training-testing data split, we performed 100 random splits and
showed the quality of separation between low and high-risk
patients in testing sets is independent of any particular data split.
(Figure S1)
Testing efficacy of prognostic indicators. Efficacy of the
prognostic indicators was tested by comparing hazard ratios and
concordances. Hazard ratios were calculated between high and
low risk groups. Concordance was estimated using the R package
clinfun [9].
Gene enrichment analysis. Testing for biological functions
and pathways overrepresented in a gene list was done using
Table 1. NCCN factors tested for association with survival.
Variable Variable Details
Univariate
Cox p-value HR [95% CI]
Multivariate Cox p-value/
HR
Stage Stage.I=66, Stage.II/III=42 0.002 2.49 [1.39–4.47], Stage.II/III vs Stage.I 0.002, HR=2.47
Age min=45 yo, med=68 yo, max=87 yo 0.03 1.04 [1.00–1.07], per year increase 0.03, HR=1.04
Gender F=55, M=53 0.74 1.10 [0.62–1.97], Female vs Male not tested
Race AA=9, Caucasian=99 0.32 2.06 [0.50–8.49], AA vs Caucasian not tested
COPD present=50, absent=54 0.2 1.47 [0.81–2.67], present vs absent not tested
Histology AD=67, LSCC=34 0.4 1.31 [0.70–2.44], AD vs LSCC not tested
Tobacco use previous=87, current=15 0.99 0.99 [0.44–2.23], previous vs current not tested
Adjuvant Chemo no=52, yes=34 0.19 1.58 [0.80–3.14], no vs yes not tested
Pack years min=0 py, med=40 py, max=188 py 0.87 1.00 [0.99–1.01], per pack increase not tested
Variable details show number of patients for categorical variables and minimum (min), median (med) and maximum (max) values for continuous variables. HR=hazard
ratio, CI=confidence interval, F=female, M=male. AD=lung adenocarcinoma, LSCC=lung squamous cell carcinoma. AA=African American, yo=years old, py=pack
years.
doi:10.1371/journal.pone.0034392.t001
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(FDR) FDR,20% and enrichment .2 fold. For a gene list with
high false discovery rate (52% for 1704 genes associated with
overall survival) we report only results that pass a threshold of
FDR,1% and also show significant enrichment by GSEA
algorithm [11,12] with FDR,25% cutoff.
Enrichment of immune cell-type specific genes. We
obtained a list of genes specifically expressed in 8 categories of
immune cell types, including T cells, B cells, NK cells, Dendritic
cells, Monocytes, Neutrophils, Lymphoid cells and Myeloid cells,
from the Immune Response in Silico (IRIS) database [13,14]. We
tested if these genes were overrepresented in our list of 1704 genes
significantly associated with overall survival. We used the Fisher
Exact test for every cell type for 3 different groups of genes
separately: 1) all significantly associated with overall survival, 2)
genes with significant HR.1 and, 3) genes with significant HR,1.
Overall, 24 tests (8 cell types63 gene groups) were performed and
we report p-values adjusted for multiple testing with Bonferroni
correction.
Gene overlaps. Significance of overlaps between two groups
of genes (with A and B number of genes) selected from the same
pool of C=20,341 expressed genes was tested using the
hypergeometric test. The expected number of overlapping genes
was calculated as (A6B)/C.
Results
Association of overall survival with clinical risk factors
Various factors were tested for association with survival by
univariate Cox regression, including tumor stage, age, gender,
race, presence of COPD, tumor histology, tobacco use and
adjuvant chemotherapy (Table 1). We found that two factors,
advanced age and tumor stage, were significantly associated with
survival with hazard ratios of 1.04 per year increase and 2.49 for
tumor stage respectively. Figure 1 demonstrates Kaplan-Meier
curves for the two factors. When these two variables were tested
together in a multivariate Cox regression model, both of them
remained statistically significant (Table 1) indicating that they are
independently associated with survival in our study population and
that our data set conforms to predicted markers of clinical
prognosis.
Prediction of overall survival by a panel of PBMC genes
In order to identify and independently validate a compact gene
panel, that could be used to predict overall survival, we divided
our 108 samples into 2 randomly selected groups of 54 samples.
We used a training set of 54 samples to select the prognostic gene
panel, and then confirmed its utility on the remaining 54 of
samples reserved as a test set. We applied multivariate Cox
regression with L1 and L2 penalized estimations [8] to the training
set, and identified 26 genes (Table 2) whose expression patterns
when combined in a linear model, best predicted the observed
survival data. For each subject, this model provides a Gene
Prognostic Score (GPS) that is calculated as a linear combination
of the expression values of the 26 prognostic genes. The GPS
assigned to each patient was found to be significantly associated
with his survival for the 54 subjects in the training set with
P=3 610
25. The performance was confirmed on the validation set
(P=0.009) demonstrating that the PBMC derived GPS is a
statistically significant predictor of overall survival on new patients.
Kaplan-Meier curves for patients from the validation set and their
assignments into either a high-risk or low-risk category based on
the median GPS are shown in Figure 2A. These studies show that
PBMC expression levels for the 26 gene probes developed on our
training set could also successfully predict survival in the validation
set and, by extension, on any new patients.
Gene expression and tumor stage data are independent
predictors of survival
We further assessed whether the GPS provided additional value
to the clinical risk factors for survival we had tested. Of these, only
age and tumor stage were found to have significant prognostic
values for our data set. Although age was significantly associated
with survival in analysis using all 108 patients’ information
(Table1), it did not have significant prognostic value when
applied to the test set of 54 samples (P=0.34). For this reason, we
did not include the age variable in the following analyses.
Based on the data from the validation set, the stage predictor
alone generated a hazard ratio of 3.0 (P=0.0095, 95% CI of 1.3 to
6.9). When used in the multivariate Cox regression model, both
Stage and GPS were significant (P=0.004 for stage and P=0.003
for GPS), indicating that the two variables are independent
predictors of overall survival and that using them together should
Figure 1. Kaplan-Meier curves for patients stratified by (A) Age and (B) Tumor Stage.
doi:10.1371/journal.pone.0034392.g001
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PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e34392Figure 2. Performance of the Gene Predictive Score (GPS). A. Kaplan-Meier curves for patients from the test set stratified by the median of
GPS calculated from expression of 26 genes. p-value for univariate Cox regression is shown. B. Kaplan-Meier curves comparing survival probabilities
for patients from testing set stratified by Stage alone and combination of Stage and GPS with 35 patients in the lower risk group (number of stage I
patients) and 19 higher risk group (number of stage II/III patients).
doi:10.1371/journal.pone.0034392.g002
Table 2. The 26 gene probes used in a calculation of the gene predictive score (GPS).
# Gene Symbol c c
norm P
1 coronin 6 CORO6 2.51 0.39 0.02
2 PREDICTED: similar to Nuclear protein 1 (prot p8) LOC650200 22.21 20.38 0.001
3 PM1-EN0060-201000-002-c07 EN0060 cDNA BF846242 24.26 20.37 0.01
4 transcription elongation factor A (SII)-like 4 TCEAL4 21.08 20.31 3610
25
5 matrix metallopeptidase 1 (interstitial collagenase) MMP1 0.82 0.22 0.02
6 cDNA clone IMAGE:6621749 5 BU854460 2.22 0.2 0.01
7 family with sequence similarity 20, member A FAM20A 0.5 0.2 0.0003
8 T cell antigen receptor alpha chain TCRVA2 20.48 20.19 0.0001
9 thioesterase domain containing 1 THEDC1 1.34 0.18 0.01
10 cDNA clone IMAGE:3643602 3 BF194881 1.55 0.16 0.05
11 glial high affinity glutamate transporter SLC1A3 0.18 0.12 0.05
12 ADAM metallopeptidase with thrombospondin type 1 motif, 2 ADAMTS2 0.73 0.12 0.01
13 low density lipoprotein receptor-related protein 8 LRP8 0.55 0.12 0.03
14 zinc finger protein 662 ZNF662 20.69 20.11 0.01
15 secretin SCT 20.51 20.09 0.01
16 C-type lectin domain family 4, member C CLEC4C 20.15 20.08 0.02
17 InaD-like (Drosophila) INADL 20.37 20.08 0.001
18 cyclin E2 CCNE2 0.36 0.08 0.001
19 kinesin family member 15 KIF15 0.19 0.06 0.004
20 cut-like 2 (Drosophila) CUTL2 20.15 20.05 0.01
21 argininosuccinate synthetase ASS 0.19 0.04 0.03
22 chromosome 5 open reading frame 20 C5orf20 20.08 20.03 0.005
23 tetraspanin 14 TSPAN14 0.08 0.03 0.01
24 PREDICTED: similar to zinc finger protein 114 LOC390372 20.19 20.02 0.1
25 C-type lectin domain family 4, member C CLEC4C 20.05 20.02 0.08
26 complement component 4 binding protein, beta C4BPB 20.04 20.01 0.01
c is a regression coefficient for the probe expression. c
norm is a c normalized over average expression among 26 probes to show relative contribution of the gene to the
final GPS and is used to rank the genes. Regression coefficient is indicative of a hazard ratio for a gene: if c.0, then HR.1, if c,0, then HR,1. P shows univariate cox
regression p-value for the gene when all 108 samples are used.
doi:10.1371/journal.pone.0034392.t002
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compared hazard ratios for stage alone to the hazard ratios for the
combined Stage+GPS factors. Stage alone split patients into 19
higher risk patients (the number of Stage II/III cases) and 35 lower
risk patients (the number of Stage I cases).
.The combined Stage+GPS predictor resulted in a significant
hazard ratio of 4.9 (P=0.0003, 95% CI of 2.1 to 11.4) between
high and low risk groups, an increase compared to the hazard ratio
shown by Stage predictor alone (HR=3.0) or GPS predictor alone
(HR=1.9). This is illustrated by the Kaplan-Meier curves
(Figure 2B).
Alternative quantitation of the ability of the gene expression
score to improve prediction of survival was performed by
determining the concordance index for the Cox regression model
for stage alone: 0.63 (0.56–7.0), GPS alone: 0.57 (0.51–0.62), and
stage+GPS: 0.69 (0.62–0.76). The increase in concordance index
along with the evidence of the independence of the two factors
supports the utility of using both the stage and gene expression
scores to determine probability of survival compared to using stage
only. This result demonstrates that a gene expression score can
add prognostic information to the traditional tumor stage variable.
Adding the GPS factor to the classification by stage resulted in
the reassignment of 6 patients between high and low risk groups.
Three of the 6 with stage I NSCLC (one IA and two IB patients)
were reassigned to the high risk group. Two of these patients
actually died within 18 months (p1240, stage IB) and 43 months
(p1183, stage IA) of the sample collection. The additional 1B
patient (p1246) remained alive for at least 65 months. This
individual was one of the youngest patients in our cohort (only 47
compared to 45 year minimum age). Inclusion of the age factor in
the model might have altered assignment to the high risk group.
The 3 other patients had stage II NSCLC. They were classified by
stage as high risk and then reassigned to the low risk group when
adding the GPS factor. All three of the patients (p1589, p1561 and
p1445) were alive at the time of status assessment (44, 46 and 56
months correspondingly). These results support the utility of a
combined GPS+stage model for more accurate estimation of
prognosis.
PBMC gene functions associated with overall survival
In order to determine whether specific functions or pathways
were represented in the PBMC gene expression patterns associated
with survival, we used univariate Cox regression to identify the
genes that were significantly associated with outcome using all 108
patient samples. We found 1704 probes that showed significance
at P,0.05 and screened those probes for enriched functions and
pathways using both DAVID and GSEA software. This analysis
revealed several highly significant functional categories with
enrichment of 2 fold or more (Table S2). In particular, a list of
32 ribosomal structure and function-related genes (enrichment of
2.3) had higher expression in patients with better survival, while
cell cycle genes in general (enrichment of 2.3) and specifically M
phase genes (enrichment of 2.2) were predominantly expressed at
lower levels in the patients with better survival.
Immune cell types associated with survival
Since gene expression was analyzed on PBMC mRNA, we
determined whether the genes significantly associated with survival
were also specific to a certain immune cell type as defined by the
Immune Response in Silico (IRIS) database [13,14]. Of the 669
immune cell-specific genes in our dataset, 79 were found to be
associated with overall survival (Table 3). We found a significant
enrichment of T-cell specific genes (23 altogether, 8 fold
overrepresentation, P=2 610
28), with 15 of the 23 genes having
HR.1 indicating a significant correlation between lower levels of
expression and improved survival. We also found that lower
expression of 21 myeloid specific genes (enrichment of 2 fold,
P=0.048) was associated with improved overall survival. Detailed
lists of genes associated with each cell type and corresponding
enrichments and p-values are listed in Table S3.
Tumor removal changes expression of survival-
associated genes
We previously showed that PBMC gene expression in the
presence of a NSCLC is significantly altered in post-surgery
PBMC samples [5,6]. We found that the expression of more than
20% (383) of the 1704 ‘‘survival’’ genes screened in this study was
also significantly changed by the surgical removal of the lung
tumor (3485 genes with p-value,0.05 by paired t-test,
FDR,20%). This is a statistically significant number compared
to the 292 gene overlap expected by chance (P=10
29 by
hypergeometric test). We identified 4 classes of outcome-associated
genes (Figure 3) that change expression levels post-surgery. Two
of the groups of genes (A and D) were significantly overrepresented
and we describe these 2 classes. The largest group (group A) of 236
genes have HR,1 (better survival for higher expression) and are
downregulated in PBMC after tumor removal. The second group
(group D) includes 92 genes with HR.1 (poorer survival with
higher expression) were upregulated in PBMC after tumor
removal. These prognostic genes, that also change expression
after the tumor is removed, could provide a new method for
determining recurrence.
Functional enrichment analysis of group A genes shows strong
overrepresentation of proteins associated with ribosomes, protein
synthesis, mitochondrial function, translational factor activities
and zinc finger proteins, characteristics consistent with PBMC
being more active in response to the tumor presence and,
apparently, better for survival. Group D shows functional
enrichment only for genes associated with red cell function
possibly indicating lower numbers of circulating erythroblasts in
the presence of a tumor, but poorer survival with higher
expression.
Discussion
The ability to accurately identify patients with lung cancer that
have a poor prognosis is particularly important for patients with
Table 3. Number of unique cell-type specific genes in a list of








T Cell 15* 83 3
B Cell 2 1 59
NK Cell 1 0 11
Dendritic Cell 2 3 41
Monocyte 6 1 45
Neutrophil 2 0 31
Lymphoid 8 9 149
Myeloid 21* 02 2 1
Table shows numbers of unique genes.
*=significantly overrepresented (Bonferroni corrected P,0.05). For more
details reference Table S3.
doi:10.1371/journal.pone.0034392.t003
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recurrence. Predicting which tumors are most likely to recur is
critical to designing treatment after surgery, in particular for stage
IA patients, which do not normally receive adjuvant chemother-
apy. Currently, the most effective prognostic indicators are
demographic characteristics (patient age, sex, smoking history)
and clinical parameters (tumor size, stage and lymph node
involvement). A number of gene expression studies on lung
tumors that present prognostic algorithms were recently reviewed
[4]. One analysis [15] trained and validated on publicly available
data describes a 5-gene prognostic signature for all stages including
stage I adenocarcinoma (but not squamous cell carcinoma). One
issue with the tumor studies has been the lack of reproducibility,
possibly because of differences in sample quality and tumor cell
representation in the samples. Approaches using blood or serum to
identify prognostic indicators avoid some of the problems
associated with tumor variability and microRNA expression
profiles in serum or plasma have been applied to both NSCLC
diagnostic [16,17] and prognostic studies by two groups [18,19].
Hu et al, [19] using serum from 243 patients, found a prognostic
set of 4 miRNAs which, when trained on half the patients could
predict survival on the remaining half. Both groups suggest that
their findings will allow separation of low from high risk patients,
improving prognosis by stage alone.
Interactions between a tumor and the immune system have long
been a subject of interest in cancer biology [20]. We previously
found that PBMC gene expression signatures could distinguish
patients with lung cancer from patients with non-malignant lung
diseases. The studies presented here demonstrate that gene
expression signatures in the peripheral immune cells of NSCLC
patients also contain information that is correlated with survival
and, like signatures obtained from lung tumors, can improve
clinical predictors of outcome. In our study, we identify a panel of
26 gene probes whose expression patterns are significantly
associated with survival and this information is independent of
information provided by tumor stage. We also show that some
genes correlated with prognosis are immune cell lineage specific.
The most striking changes were in the myeloid specific genes
which show an inverse correlation between expression and
survival. As shown in Table S3, 29 of the 30 genes specifically
associated with monocytes, neutrophils, or ‘‘myeloid cells’’, have
increases in expression in patients with decreased survival times.
These data are consistent with observations that an increase in
immature myeloid cell populations in the blood and in tumors are
associated with advanced cancers and poor prognosis, likely due to
ability of these cells to promote angiogenesis and to suppress anti-
tumor immune responses [21,22,23,24]. High numbers of
neutrophils have been shown to be predictors of poor prognosis
in melanoma, ovarian cancer and head and neck cancer [25].
Prognosis-associated T-cell genes also have predominantly higher
hazard ratios but the mechanism by which these genes affect
patient survival is not yet clear.
A significant number of PBMC genes that change in expression
after the removal of a tumor are also associated with prognosis.
The largest class (group A, Figure 3) includes genes which are
expressed at higher levels in the presence of a tumor compared to
samples from the same patient taken after the tumor removal and
whose higher expression indicates better survival. The most
differentially expressed gene in this group is the immune response
gene CXCR4, important for lymphocyte trafficking [26,27]. Its
ligand, SDF-1/CXCL12, is a key factor directing dendritic cell
migration associated with an adaptive immune response [27,28] In
contrast, another large group of genes (group D) show the opposite
behavior having high hazard ratios indicating poor survival
function and lower levels in the presence of a tumor. DAVID
analysis of this gene class shows enrichment for genes significantly
associated with functions of oxygenation, hypoxia and iron
binding (HGBD, HGB1, HGB2) and erythroid associated factor
(ERAF). These are presumably constituents of the erythroblasts
known to co-purify with the PBMC [29,30]. Lower expression of
these genes in the presence of the tumor may indicate that
erythroblast gene expression (or erythroblast numbers) is repressed
in agreement with other studies, as poor oxygenation and anemia
have been previously associated with lung cancer [31,32].
Relatively higher expression of these genes in patients with poorer
survival could be due to the increased presence of erythroblasts in
response to the deteriorating oxygenation associated with more
serious disease. Overall, the significant overrepresentation of genes
from groups A and D suggests that measuring the change of those
genes between paired pre- vs post- surgery samples from the same
patient, might reflect the immune system’s ability to respond to the
tumor, and may provide added information for outcome
prediction by comparing samples collected before with samples
collected after tumor removal. In addition, genes from those
groups may be candidates to reassess cancer recurrence probabil-
ities in regular post-surgery blood samples.
The use of combined prognostic factors including clinical stage,
tumor gene expression signature and PBMC gene signatures could
provide additional guidance for prescribing adjuvant chemother-
apy for early stage cancers that presently would not otherwise be
treated after surgery. We find that the gene expression from
patient PBMC is an independent predictor of survival, and that
when PBMC gene expression is combined with information from
cancer stage, the hazard ratio from stage alone is increased from
3.0 to 4.9. The limited size of the dataset has not permitted testing
for prognosis within a single cancer stage, but we find that two
Figure 3. Characterization of genes whose expression changes
after tumor removal and are also associated with survival. #
obs.=observed number of genes; # exp.=expected number of genes
by chance; Pre=expression in pre-surgery sample; Post=expression in
post-surgery sample; HR=Hazard Ratio for high vs low expression of
the gene.
doi:10.1371/journal.pone.0034392.g003
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combining the GPS blood signature with stage based prognosis.
The evolution of a malignant tumor includes interactions
among cancer cells and signaling with other cells in the tumor
microenvironment including immune cells. Our studies suggest
that these interactions are not only localized to the tumor site but
also extend to the peripheral immune system and that information
related to prognosis or recurrence is present in the gene expression
profiles of the peripheral immune cells. In contrast to tumor-based
prognostic signatures that reflect malignancy, PBMC based
prognostic signatures reflect the type and strength of the immune
response to the tumor presence. It is likely that by combining
clinical characteristics for survival derived from tumors at the time
of surgery with repeated assessments of PBMC derived GPS data,
a more robust algorithm for predicting recurrence can be
developed that can be reassessed at various intervals after surgery.
In addition, the genes of immune cells associated with patient
outcomes might be targets for clinical manipulation to alter key
gene expression in order to potentiate the anti-tumor immune
response and help to reduce the incidence of recurrence.
While additional studies with larger numbers of racially diverse
patients need to be carried out, the present study demonstrates
that statistically significant outcome information can be detected in
the gene expression patterns of PBMC from NSCLC patients.
Efforts to collect the appropriate samples to address these issues
are ongoing.
Supporting Information
Figure S1 Distribution of p-values for applying model
fit on training set to testing set samples. To test the
generality of our approach, we performed 100 random selections
of training/testing sets to estimate the possibility that our result
can be accounted by a fortuitous selection of patients. Based on
distribution of p-values that show significance of performance on
the test set, we saw 39% of the test sets reached a statistical
significance of P,0.05. This is an enrichment of 7.8 fold over a
random p-value distribution (P=4 610
29, Fisher exact test).
(TIF)
Table S1 Demographics and survival data for patients.
S=current smoker (n=15), Q=quit smoking (n=23 with ,1
year before surgery, n=64 with $1 year before surgery),
N=never smoker (6), C=Caucasian, AA=African American,
M=male, F=female, y=yes, n=no, un=unknown, AD=
adenocarcinoma, LSCC=lung squamous cell carcinoma,
NSCLC=non-small cell lung cancer, a=alive, d=deceased.
(XLS)
Table S2 Enriched annotation categories in the list of
genes significantly associated with survival. Results are
based on univariate cox proportional hazard model. E=enrich-
ment, Sensitivity shows how many of genes are in the list/how
many total known (resulting percentage), FDR=false discovery
rate from the DAVID software. HR=hazard ratio, and ,1
indicates number of genes with higher expression in patients
associated with better survival, while .1 indicates number of
genes with higher expression in patients associated with poor
survival. All results showed FDR,25% by GSEA analysis.
(XLS)
Table S3 Expanded Table 3 showing unique cell-type
specific genes. The table shows number of genes in a list of
1704 probes (1450 unique genes) significantly associated with
survival. ‘+’ indicates genes with HR.1 (higher expression=-
worse survival). ‘-’ indicates genes with HR,1 (higher expres-
sion=better survival). S=number of significant genes specific to
the cell type. NS=number of non-significant genes specific to the
cell-type. E=enrichment of the cell-type specific genes among all
significant genes. p=right-tail Fisher Exact Test nominal p-values
with Bonferroni corrected p-values (24 tests=8 cell types63 gene
sets) shown in parenthesis.
(XLS)
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